The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
Twitter and Facebook have suspended accounts believed to be tied to a state-backed disinformation campaign originating from inside China.Technologyread more
Beijing will lower borrowing costs for companies, but that may not boost the economy as much as some hope.China Economyread more
United States Steel Corp will temporarily lay off hundreds of workers at its Great Lakes facility in Michigan in coming weeks, according to a filing the steelmaker made with...US Marketsread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
Stocks are bouncing higher but could be trapped in a range longer term, until there's a resolution of the trade wars.Market Insiderread more
Stocks in Asia edged higher Tuesday morning as investors await the release of minutes from the Reserve Bank of Australia's July meeting. The People's Bank of China is also set...Asia Marketsread more
Powell will have the opportunity if not to walk back the "midcycle" assessment then to at least provide some further explanation about what it means.Economyread more
Apple has spent more than $6 billion on original TV shows and movies for its forthcoming Apple TV+ service, according to a Financial Times report on Monday.Technologyread more
The Business Roundtable, led by Jamie Dimon, gives a new definition of the "purpose of a corporation."Marketsread more
"These days, the consumer is addicted to convenience ... If it doesn't have a great digital presence or incredible bargains, take a pass," Jim Cramer says.Mad Money with Jim Cramerread more
Surescripts is upping its battle with Amazon-owned PillPack, accusing a third company of providing PillPack with patient prescription information "fraudulently," and turning the matter over to the FBI. It's the latest in a series of moves that could make it harder for Amazon to enter the prescription drug market.
Americans are spending an excessive amount on prescription drugs, the cost of which likely topped $330 billion in 2018. Amazon made its first steps into the space in 2018, when it acquired online pharmacy start-up called PillPack.
A year later, Amazon is engaged in a tense battle with one of the largest incumbents in the space. Surescripts is owned by a coalition of potential PillPack competitors, including CVS and ExpressScripts, and manages about 80% of all U.S. prescriptions. It is such a dominant force that in April, the Federal Trade Commission sued the company, alleging "illegal monopolization of e-prescription markets."
The battle is the latest in a string of disputes between Amazon and the established pharmacy companies since the PillPack deal — a deal that sent shares of pharmacy owners and pharmacy benefit managers tumbling. Earlier this year, CVS filed a lawsuit against a former employee after he told the company he would be taking a job at PillPack. A judge blocked the employee from working for PillPack for 18 months.
The dispute centers on how PillPack gets information about customers' prescriptions, so it can provide them automatically when users sign up, rather than making them enter each prescription by hand.
Until recently, PillPack contracted with a company called ReMy Health, which in turn gets information about customer prescriptions from Surescripts.
In July, CNBC reported that ReMy was cutting PillPack off from this data. Amazon suspected Surescripts was behind the move, and sent a cease-and-desist letter to the company, according to a person familiar with the deliberations who asked not to be named discussing private business matters.
Now Surescripts, in a statement issued on Monday, says ReMy Health gave "fraudulent information" to Surescripts to get the prescription data, in violation of the companies' contracts.
Specifically, Surescripts says that ReMy claimed to be getting the prescription information for "providers caring for patients in hospitals," when in fact it was providing it to PillPack. Surescripts also claims that PillPack was using National Provider Identifiers (NPIs) that belonged to health-care providers who had never seen the patients. PillPack, in response, noted all requests for patient information are made with "explicit consent of our customers and all information we provide is accurate."
In a statement, Surescripts added: "We are still investigating the full scope of these improper activities but today are taking immediate steps to protect the data our partners entrusted to us and the privacy of our patients they serve. Specifically, we have suspended ReMy Health from our network, are terminating their contract, and are turning the matter over to the FBI for further investigation."
Surescripts told CNBC in an interview that its counsel has been in touch with Amazon's lawyers, but declined to comment further.
"It's not lost on us that PillPack is owned by one of the largest industrial organizations in the country but our focus is not on what they want. It's on the trust associated with the network and the privacy of patients," said CEO Tom Skelton in an interview with CNBC.
A PillPack spokesperson said in response that, as a pharmacy, it needs to check the medication histories of patients in case there are issues related to drug interractions, and that customers authorize them to analyze their personal data.
"Given that Surescripts is, to our knowledge, the sole clearinghouse for medication history in the United States, the core question is whether Surescripts will allow customers to share their medication history with pharmacies," the spokesperson said. "And if not, why not?"